CONNECT WITH US
HealthTech

HealthTech

China could ‘corner’ biopharma sector with new plan, US panel warns

Healthcare Dive logo

Published on

Add as a preferred source on Google
China could ‘corner’ biopharma sector with new plan, US panel warns

A commission called on U.S. lawmakers to act quickly to prevent an “overdependence” on China that could leave American patients “vulnerable to supply chain weaponization.”

Even before the release of its latest biotech plan, China’s rise as a global pharmaceutical powerhouse had already rung alarm bells in Congress as well as the corporate suites of top drugmakers. Its new goal of ensuring the country produces a quarter of the world’s “first-in-class drugs” by 2030 has intensified concerns that the U.S. might soon lose a long-held edge and become overly dependent on China for new medicines.

The commission, an 11-member group that includes members of Congress, was formed by defense appropriations legislation in 2022 to study the state of biotechnology competition between the U.S. and other countries, particularly China. Its goal is to promote legislation to support the biotech industry, much as work by an earlier commission helped pave the way for the 2022 CHIPS Act aimed at semiconductor manufacturing and research.

The latest publication focuses on the kind of cross-border licensing deals that have become commonplace over the last few years. A large proportion of these transactions are based on preclinical research and are rising in value, signaling “a growing trust in China’s ability to innovate in the pharmaceutical sector.” The commission also pointed to “escalating deal structures” and repeat collaborations, which could transfer to China-based partners key knowledge such as “development, commercialization, and regulatory best practices for U.S. markets.”

S. joint ventures into Chinese markets in the automobile, semiconductor, and industrial chemical sectors.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.